Filing Analysis
OmniAb, Inc. announced the appointment of Amechi Nwachuku as Chief Operating Officer, effective July 13, 2026. Mr. Nwachuku brings extensive leadership experience from major life sciences companies including Thermo Fisher Scientific and Danaher.
📋 Key Facts
- Amechi Nwachuku appointed as COO effective July 13, 2026.
- Annual base salary set at $445,000 with a target bonus of 45%.
- Signing bonus of $20,000 granted.
- Grant of 800,000 stock options vesting over four years, starting August 1, 2026.
- Includes provisions for severance and change in control benefits.
OmniAb, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 17, 2026. The meeting resulted in the election of two Class I directors and the ratification of Ernst & Young LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting of Shareholders held on June 17, 2026.
- Jennifer Cochran, Ph.D. was elected as a Class I director (57,948,696 For / 25,997,984 Withheld).
- Matthew W. Foehr was elected as a Class I director (82,231,849 For / 1,714,831 Withheld).
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (102,163,551 For / 112,653 Against).
OmniAb, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report was filed on May 7, 2026, to announce financial results for the quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release dated May 7, 2026, was furnished as Exhibit 99.1.
- The company is an emerging growth company as defined in Rule 405 of the Securities Act.
OmniAb, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, through a press release furnished on March 4, 2026.
📋 Key Facts
- The filing reports financial results for the three months and full year ended December 31, 2025.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A press release was issued on March 4, 2026, and included as Exhibit 99.1.
- The company is an emerging growth company as defined in Rule 405 of the Securities Act.
OmniAb, Inc. has adopted amended and restated bylaws effective January 30, 2026. The changes primarily focus on aligning company governance with SEC universal proxy rules and modernizing procedures for stockholder nominations.
📋 Key Facts
- Board of Directors approved and adopted Amended and Restated Bylaws on January 30, 2026.
- Amendments address compliance with SEC universal proxy rules (Rule 14a-19).
- New procedures established for stockholder nominations and proposals to enhance disclosure requirements regarding proposing stockholders and nominees.
- Includes technical, modernizing, and clarifying changes to existing bylaws.
OmniAb, Inc. filed an 8-K to furnish its quarterly earnings press release for the three and nine months ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of financial results for the period ending September 30, 2025.
- The report was filed on November 4, 2025.
- The company is an emerging growth company as defined by the SEC.
OmniAb, Inc. entered into a securities purchase agreement for a private placement of 21,254,106 shares at $1.40 per share (or $1.85 for insiders), aiming to raise approximately $30 million in gross proceeds. The funds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution likely due to the issuance of over 21 million new shares.
- Insider participation in the offering at a higher price ($1.85 vs $1.40) suggests potential non-arm's length transaction dynamics, though common in private placements.
- The need for $30M specifically for 'working capital' often indicates a tight cash runway in micro-cap biotech firms.
📋 Key Facts
- Private placement of 21,254,106 shares of common stock.
- Pricing: $1.40 per share for standard purchasers; $1.85 per share for officers, directors, employees, or consultants.
- Expected gross proceeds: ~$30.0 million before fees and expenses.
- Closing date expected on August 26, 2025.
- Leerink Partners acted as the placement agent.
- Company must file a registration statement for resale within 45 days of closing.
- Lock-up period: Company, officers, and directors are prohibited from selling stock for 60 days.
OmniAb, Inc. filed an 8-K to furnish its quarterly earnings press release for the three and six months ended June 30, 2025.
📋 Key Facts
- Report date: August 6, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes Exhibit 99.1 (Press Release)
- Company is an emerging growth company
OmniAb, Inc. held its 2025 Annual Meeting of Shareholders on June 17, 2025. The filing reports the final voting results for the election of two Class III directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 17, 2025.
- Carolyn R. Bertozzi, Ph.D. elected to Class III director (36,153,128 votes 'For').
- John Higgins elected to Class III director (53,835,964 votes 'For').
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Ratification of auditor received 84,233,643 votes 'For'.
OmniAb, Inc. filed an 8-K to furnish its quarterly press release announcing financial results for the three months ended March 31, 2025.
📋 Key Facts
- The filing is a routine announcement of quarterly financial results (Q1 2025).
- Reporting period: Three months ended March 31, 2025.
- Filed on May 8, 2025.
- The information in the press release is furnished under General Instruction B.2 and is not 'filed' for purposes of Section 18 liability.
OmniAb, Inc. announced the appointment of two new independent directors, Steven C. Crouse and Philip J. Gotwals, Ph.D., to its Board of Directors. Concurrently, Sarah Boyce resigned from the Board effective April 18, 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Appointed Steven C. Crouse as a Class II director; he joins the Audit and Science and Technology Committees.
- Appointed Philip J. Gotwals, Ph.D., as a Class II director; he joins the Human Capital Management and Compensation and Science and Technology Committees.
- Both new directors were granted 40,000 RSUs and options to purchase 80,000 shares, vesting over three years in equal annual installments.
- Sarah Boyce resigned from the Board and all committees effective April 18, 2025; the company stated her resignation was not due to any disagreement with operations or management.
- The Board size increased from six to seven members.
OmniAb, Inc. filed an 8-K to announce its financial results for the three months and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 18, 2025
- Reporting period: Three months and full year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Company is an emerging growth company.
OmniAb, Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
OmniAb, Inc. filed an 8-K to furnish its quarterly press release announcing financial results for the three and six months ended June 30, 2024.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Three and six months ended June 30, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
- Company is an emerging growth company.
OmniAb, Inc. announced the resignation of Joshua Tamaroff from the Board of Directors and Audit Committee effective June 28, 2024. The departure is due to his exit from Avista Capital Partners and was not due to any disagreement with the company.
🚩 Red Flags
- Loss of a board member designated by a major stakeholder (Avista Capital Partners).
📋 Key Facts
- Joshua Tamaroff resigned from the Board and Audit Committee on June 27, 2024, effective June 28, 2024.
- The resignation is linked to Mr. Tamaroff's pending departure from Avista Capital Partners.
- Avista Acquisition LP II (the designee) does not intend to appoint a successor for the Board seat.
- Sarah Boyce, an existing independent director, was appointed to fill the Audit Committee vacancy.
- The Board size was reduced from seven members to six following the resignation.
OmniAb, Inc. held its 2024 Annual Meeting of Shareholders on June 18, 2024. The filing reports the final voting results for the election of two Class II directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of Shareholders held on June 18, 2024.
- Sarah Boyce was elected to a three-year term as Class II director (61,512,919 votes 'For').
- Steve Love was elected to a three-year term as Class II director (80,325,457 votes 'For').
- Shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
OmniAb, Inc. filed an 8-K to furnish its quarterly earnings press release for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Three months ended March 31, 2024
- The filing is a standard earnings release under Item 2.02
- Information provided in Exhibit 99.1 is furnished, not filed, per General Instruction B.2 of Form 8-K
OmniAb, Inc. filed an 8-K to furnish its press release announcing financial results for the three months and full year ended December 31, 2023.
📋 Key Facts
- Report date: March 20, 2024
- Reporting period: Three months and full year ended December 31, 2023
- The filing is a routine announcement of financial results via press release (Exhibit 99.1)
- Company is an emerging growth company